CARGO Therapeutics,

About CARGO Therapeutics,

Cargo Therapeutics (NASDAQ:CRGX) is a clinical-stage biopharmaceutical company developing innovative medicines for hematologic malignancies, which are cancers of the blood and blood-forming tissues. Their lead candidate, rocatribor, is a targeted small molecule inhibitor currently in Phase 2 clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cargo Therapeutics aims to leverage its scientific expertise and collaborative partnerships to bring life-changing therapies to patients with these challenging diseases.

What is CARGO Therapeutics, known for?

Snapshot

2019

Year founded

118

Employees

California, United States

Head office

Loading Map...

Operations

All Locations

United States

Products and/or services of CARGO Therapeutics,

Rocatribor: A targeted small molecule inhibitor currently in Phase 2 clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
CAR-T cell therapy: A personalized cellular therapy approach that involves engineering a patient's T cells to recognize and attack cancer cells.
CAR-NK cell therapy: Another form of cellular therapy using natural killer (NK) cells, which have the innate ability to recognize and kill cancer cells.
Bispecific T cell engagers (BiTEs): A type of immunotherapy that uses molecules to link T cells to cancer cells, triggering the immune system to destroy the cancer cells.
TCR-T cell therapy: A cellular therapy approach that uses T cells engineered with a specific T cell receptor (TCR) to recognize and target cancer cells.
Gene editing therapies: A new frontier in cancer treatment that uses technologies like CRISPR to modify genes and potentially cure cancer.